The Kerala High Court has asked the Centre to collect nationwide data on the affordability of patented life-saving medicines, including cancer drugs, and assess whether existing measures are helping patients access costly treatments.
The court’s direction comes amid concerns over the high prices of patented medicines and the financial burden faced by patients requiring long-term or specialised treatment. It also asked the Centre to examine whether existing price-control mechanisms and subsidy measures are effectively improving access to these medicines.
According to the proceedings cited in the case, the court held that the government has legal powers to intervene when patented medicines become prohibitively expensive. However, it did not direct the Centre to immediately exercise those powers or set a specific deadline for taking action.
The distinction means that while the court has sought evidence and an assessment of the existing system, it has not ordered an immediate reduction in the prices of patented cancer medicines.
The affordability of cancer treatment remains a major concern because patients can face substantial expenses for medicines, hospital care and other medical requirements. Patented medicines can be particularly costly when there are limited alternatives available.
The Centre’s proposed assessment could provide a broader picture of medicine prices and the effectiveness of current support mechanisms across India. However, the immediate impact on patients will depend on the government’s response and any subsequent policy decisions.
The case highlights the continuing debate over how India can balance patent protection and pharmaceutical innovation with access to essential medicines at prices patients can afford.
